Acorda to Present at the Deutsche Bank 42 nd Annual Healthcare
Conference
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present at the Deutsche Bank 42nd Annual Healthcare Conference in Boston on Thursday, May 4, 2017 at
11:20 a.m. EDT.
A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website
at www.acorda.com, or you may use the link:
http://edge.media-server.com/m/p/j5ysy24t
An archived version of this webcast will be available until June 2, 2017 on the Investors section of www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and
improve the lives of people with neurological disorders. Acorda has a pipeline of novel neurological therapies addressing a range
of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies,
including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. For more information, please visit the Company’s website:
www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to
risks and uncertainties that could cause actual results to differ materially, including: the ability to realize the benefits
anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally
subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired
programs generally improves over time; the ability to successfully integrate Biotie’s operations and Civitas’ operations,
respectively, into our operations; we may need to raise additional funds to finance our expanded operations and may not be able to
do so on acceptable terms; our ability to successfully market and sell Ampyra (dalfampridine) Extended Release Tablets, 10 mg in
the U.S., which will likely be materially adversely affected by the recently announced court decision in our litigation against
filers of Abbreviated New Drug Applications (each, an “ANDA”) to market generic versions of Ampyra in the U.S.; third party payers
(including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and
may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from
future studies of Ampyra or from our other research and development programs, including INBRIJA (CVT-301, levodopa inhalation
powder), or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval
for, or successfully market INBRIJA, any other products under development, or the products that we acquired with the Biotie
transaction; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain and maintain
regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaborator Biogen in
connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims
of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and failure to
comply with regulatory requirements could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on
these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any
intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press
release.
Acorda Therapeutics
Felicia Vonella, 914-326-5146
fvonella@acorda.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170502005220/en/